Skip to main content

Johnson & Johnson (JNJ-N) Quote - Press Releases

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019
- PR Newswire - 1 hour ago
PR Newswire - CMTX
1 hour ago
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen's 12 accepted abstracts are an oral presentation reporting updated overall survival results from the ERLEADA® (apalutamide) Phase 3 SPARTAN study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the ERLEADA® Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC), demonstrating preservation of overall health-related quality of life; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD).
UM Names Anthony Plant EVP, Global President, J3
- PR Newswire - Mon Sep 16, 4:30PM CDT
PR Newswire - CMTX
Mon Sep 16, 4:30PM CDT
UM, the full-service marketing and media agency network of IPG Mediabrands, today announced the appointment of Anthony Plant to EVP, Global President of J3, UM's full-service dedicated media unit for Johnson & Johnson. Effective immediately, Plant will oversee the agency's largest global client, with a focus on advancing Johnson & Johnson's goals, plans and ambitions and implementing best-in-class media planning at the global, regional and local levels. Plant succeeds Eileen Kiernan, who was recently elevated to Global CEO, UM.
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
- PR Newswire - Mon Sep 16, 10:30AM CDT
PR Newswire - PRNW
Mon Sep 16, 10:30AM CDT
NEW YORK , Sept. 16, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500 ® stock buybacks , or share repurchases, were $164.5 billion . This was the second consecutive quarterly decline after four consecutive quarters of record buybacks. Q2 2019 buybacks were 20.1% lower than Q1 2019's $205.6 billion , 13.7% lower year-over-year from Q2 2018's $190.6 billion , and 26.2% lower than the Q4 2018 record expenditure of $223.0 billion .  
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
- PR Newswire - Mon Sep 16, 10:30AM CDT
PR Newswire - CMTX
Mon Sep 16, 10:30AM CDT
S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the second consecutive quarterly decline after four consecutive quarters of record buybacks. Q2 2019 buybacks were 20.1% lower than Q1 2019's $205.6 billion, 13.7% lower year-over-year from Q2 2018's $190.6 billion, and 26.2% lower than the Q4 2018 record expenditure of $223.0 billion.
Janssen Submits Application to U.S. FDA Seeking First-in-Class Approval of TREMFYA® (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
- PR Newswire - Mon Sep 16, 6:30AM CDT
PR Newswire - CMTX
Mon Sep 16, 6:30AM CDT
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of TREMFYA® (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA). Developed by Janssen, TREMFYA is a human monoclonal antibody against the p19 subunit of interleukin (IL)-23. TREMFYA is the first approved selective IL-23 inhibitor. It was approved in the U.S. in July 2017 for the treatment of adult patients with moderate to severe plaque psoriasis and has also been approved in Canada, the European Union, Japan and several other countries worldwide.
Johnson & Johnson Vision Introduces TECNIS Synergy(TM) IOL, a Continuous-Range-of-Vision Intraocular Lens (IOL) at the ESCRS 2019 Congress
- PR Newswire Europe - Mon Sep 16, 2:00AM CDT
PR Newswire Europe - CMTX
Mon Sep 16, 2:00AM CDT
- TECNIS Synergy(TM) IOL delivers continuous high-contrast vision for patients with cataracts from far through near, even in low-light conditions'
New DARZALEX® (daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible
- PR Newswire - Sun Sep 15, 7:00AM CDT
PR Newswire - CMTX
Sun Sep 15, 7:00AM CDT
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone. The data, selected as a late-breaking abstract, were presented at the 17th International Myeloma Workshop (IMW) meeting in Boston.
New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)
- PR Newswire - Wed Sep 11, 9:00AM CDT
PR Newswire - CMTX
Wed Sep 11, 9:00AM CDT
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results from the Phase 3 OPTIMUM study for ponesimod, an investigational selective S1P1 receptor modulator, showing superior efficacy on the primary endpoint and most secondary endpoints compared to Aubagio® (teriflunomide)* 14 mg in adults with relapsing multiple sclerosis (MS).
Two innovative spin-out companies from Children's National Health System selected by Johnson & Johnson Innovation - JLABS to join JLABS locations in Philadelphia and Boston
- PR Newswire - Tue Sep 10, 11:18AM CDT
PR Newswire - CMTX
Tue Sep 10, 11:18AM CDT
AlgometRx and Adipomics, two companies that spun out of innovations discovered at Children's National Health System, have been selected by Johnson & Johnson Innovation - JLABS to join JPOD @ Philadelphia and JPOD @ Boston, respectively.
Oncology Drugs Market Is Expected to Grow at A CAGR of 12.7% Over the Forecast Period Owing to Rising Number of Pipeline Cell-Therapy Products, Says Absolute Markets Insights
- PR Newswire - Tue Sep 10, 8:41AM CDT
PR Newswire - CMTX
Tue Sep 10, 8:41AM CDT
In the recent past, the FDA approved cell therapies to treat CD19-positive hematological cancers. This have in turn encouraged research institutes to indulge themselves in substantial Research & Development to innovate more number of cell therapies associated with Cancer. Such a factor is expected to aid the global oncology drugs market over the forecast period. However, side-effects associated with these drugs has critically impacted the global industry growth in recent years. The global cancer cell therapy pipeline includes 1,011 active agents. Amongst them, the chimeric antigen receptor (CAR)-T cell therapy number has increased substantially and is cumulating to a total of 568 agents. Such a trend is expected to propel the overall oncology drug market growth in future years.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).